Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 21, Issue 14, 2003, Pages 2645-2650

  Altorki, Nasser K ^a   Keresztes, R S ^a   Port, J L ^a   Libby, D M ^a   Korst, R J ^a   Flieder, D B ^a   Ferrara, C A ^a   Yankelevitz, D F ^a   Subbaramaiah, K ^a   Pasmantier, M W ^a   Dannenberg, A J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PACLITAXEL; PROSTAGLANDIN E2; ANTINEOPLASTIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; ADULT; AGED; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; LUNG RESECTION; LUNG TUMOR; MALE; MAXIMUM TOLERATED DOSE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PREOPERATIVE CARE; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL; PNEUMONECTOMY; PREOPERATIVE CARE; PYRAZOLES; SULFONAMIDES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0042631411     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.07.127     Document Type: Article

References (47)

1. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111:1710-1717, 1997
2. Pisters KMW, Ginsberg RJ, Giroux DJ, et al: Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. J Thorac Cardiovasc Surg 119:429-439, 2000
3. Rosell R, Gomez-Codina J, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 330:153-158, 1994
4. Depierre A, Milleron B, Moro-Sibilot D, et al: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except TIN0), II, and IIIA non-small-cell lung cancer. J Clin Oncol 20:247-253, 2002
5. Wolff H, Saukkonen K, Anttila S, et al: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58:4997-5001, 1998
6. Soslow RA, Dannenberg AJ, Rush D, et al: COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 89:2637-2645, 2000
7. Tucker ON, Dannenberg AJ, Yang EK, et al: Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59:987-990, 1999
8. Chan G, Boyle JO, Yang EK, et al: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59:991-994, 1999
9. Tsujii M, Kawano S, Tsuji S, et al: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716, 1998
10. Williams CS, Tsujii M, Reese J, et al: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105:1589-1594, 2000
11. Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306-1311, 2000
12. Leahy KM, Ornberg RL, Wang Y, et al: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62:625-631, 2002
13. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94:3336-3340, 1997
14. Dohadwala M, Luo J, Zhu L, et al: Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 276:20809-20812, 2001
15. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 83:493-501, 1995
16. 2 in human colon cancer cells. Cancer Res 58:362-366, 1998
17. Balch CM, Dougherty PA, Cloud GA, et al: Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 95:71-77, 1984
18. 2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol 154:3383-3390, 1995
19. Plescia OJ, Smith AH, Grinwich K: Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci U S A 72:1848-1851, 1975
20. Huang M, Stolina M, Sharma S, et al: Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58:1208-1216, 1998
21. Stolina M, Sharma S, Lin Y, et al: Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164:361-370, 2000
22. 716 knockout mice by inhibition of cyclooxygenase-2 (Cox-2). Cell 87:803-809, 1996
23. Tiano HF, Loftin CD, Akunda J, et al: Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 62:3395-3401, 2002
24. Sawaoka H, Kawano S, Tsujii S, et al: Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 274:01061-1067, 1998
25. Nishimura G, Yanoma S, Mizuno H, et al: A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 90:1152-1162, 1999
26. Sheng H, Shao J, Kirkland SC, et al: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99:2254-2259, 1997
27. Kawamori T, Rao CV, Seibert K, et al: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:409-412, 1998
28. Jacoby RF, Seibert K, Cole CE, et al: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 60:5040-5044, 2000
29. Harris RE, Alshafie GA, Abou-Issa H, et al: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60:2101-2103, 2000
30. Fischer SM, Lo HH, Gordon GB, et al: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 25:231-240, 1999
31. Rioux N, Castonguay A: Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 58:5354-5360, 1998
32. Grubbs CJ, Lubet RA, Koki AT, et al: Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60:5599-5602, 2000
33. Shiotani H, Denda A, Yamamoto K, et al: Increased expression of cyclooxygenase-2 protein and 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res 61:1451-1456, 2001
34. Alshafie GA, Abou-Issa HM, Seibert K, et al: Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 7:1377-1381, 2000
35. Liu XH, Kirschenbaum A, Yao S, et al: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 164:820-825, 2000
36. Tomozawa S, Nagawa H, Tsuno N, et al: Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer 81:1274-1279, 1999
37. Subbaramaiah K, Hart JC, Norton L, et al: Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2: Evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways. J Biol Chem 275:14838-14845, 2000
38. Trifan OC, Durham WF, Salazar VS, et al: Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 62:5778-5784, 2002
39. Hsueh CT, Chiu CF, Kelsen DP, et al: Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. Cancer Chemother Pharmacol 45:389-396, 2000
40. Milas L, Kishi K, Hunter N, et al: Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 91:1501-1504, 1999
41. Pyo H, Choy H, Amorino GP, et al: A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 7:2998-3005, 2001
42. Hida T, Kozaki K, Ito H, et al: Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase-2 inhibitor, JTE-522, and conventional anticancer agents. CHn Cancer Res 8:2443-2447, 2002
43. Steinbach G, Lynch PM, Phillips RKS, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in Familial Adenomatous Polyposis. N Engl J Med 342:1946-1952, 2000
44. Lorenz M, Slaughter HS, Wescott DM, et al: Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice. Exp Hematol 27:1494-1502, 1999
45. Mizuno H, Sakamoto C, Matsuda K, et al: Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by specific antagonist delays healing in mice. Gastroenterology 112:387-397, 1997
46. Boolbol SK, Dannenberg AJ, Chadburn A, et al: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56:2556-2560, 1996
47. Dannenberg AJ, Altorki NK, Boyle JO, et al: Cyclo-oxygenase-2: A pharmacological target for the prevention of cancer. Lancet Oncol 2:544-551, 2001